Phase I Study of LB-100 With Docetaxel in Solid Tumors
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of an investigational drug called LB-100 for
Injection for treatment of solid tumors, when given with or without docetaxel. LB-100 is a
small molecule that in laboratory and animal studies has shown activity when used by itself
or together with drugs approved to treat some types of cancer (chemotherapeutic agents).
Docetaxel is a drug that has been approved for the treatment of some types of cancer; one of
the trade names for docetaxel is Taxotere®. The study is in 2 parts. Part 1: Patients will
receive injections of LB-100. Part 2: Patients will receive injections of LB-100 and
docetaxel. This is the first study where LB-100 for Injection will be used in humans.